Sun enjoys fleeting profit boost from oxaliplatin

Talk about a rollercoaster: Sun Pharma profits tripled in the first quarter, driven by one-time U.S. sales of chemotherapy drug oxaliplatin. But, alas, the generics maker stopped manufacturing the drug at the end of June, to avoid infringing the Sanofi Aventis patent. Sun has filed suit against Sanofi in the U.S. and says it will begin making the drug again in the event of a positive court ruling. Article